Medullary thyroid carcinoma: Targeted therapies and future directions

Journal of Oncology

Volumn , Issue , 2009, Pages

  Chen, Herbert ^a   Pinchot, Scott N ^a   Kunnimalaiyaan, Muthusamy ^a   Sippel, Rebecca S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CALCITONIN; EPIDERMAL GROWTH FACTOR; GEFITINIB; IMATINIB; LITHIUM; MOTESANIB; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PAZOPANIB; PROTEIN C JUN; PROTEIN P53; PROTEIN RET; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR MASH1; VALPROIC ACID; VANDETANIB; VORINOSTAT; XL 184;

CALCITONIN BLOOD LEVEL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; FATIGUE; GENOTYPE; HUMAN; HYPERTENSION; IN VITRO STUDY; METASTASIS; MICRODISSECTION; ONCOGENE C FOS; ONCOGENE C MYC; PATHOGENESIS; PHENOTYPE; PROTEINURIA; REVIEW; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

EID: 75449097942     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/183031     Document Type: Review

References (53)

1. Sippel R. S., Kunnimalaiyaan M., Chen H., Current management of medullary thyroid cancer Oncologist 2008 13 5 539 547
2. Ball D. W., Medullary thyroid cancer: monitoring and therapy Endocrinology and Metabolism Clinics of North America 2007 36 3 823 837
3. Ball D. W., Medullary thyroid cancer: therapeutic targets and molecular markers Current Opinion in Oncology 2007 19 1 18 23
4. Machens A., Ukkat J., Hauptmann S., Dralle H., Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis Archives of Surgery 2007 142 3 289 294
5. Moley J. F., Lairmore T. C., Phay J. E., Hereditary endocrinopathies Current Problems in Surgery 1999 36 9 653 762
6. Chen H., Roberts J. R., Ball D. W., Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection Annals of Surgery 1998 227 6 887 895
7. Kebebew E., Kikuchi S., Duh Q.-Y., Clark O. H., Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer Archives of Surgery 2000 135 8 895 901
8. Moley J. F., Medullary thyroid cancer Surgical Clinics of North America 1995 75 3 405 420
9. Chen H., Kunnimalaiyaan M., Van Compel J. J., Medullary thyroid cancer: the functions of Raf-1 and human achaete-scute homologue-1 Thyroid 2005 15 6 511 521
10. Kunnimalaiyaan M., Traeger K., Chen H., Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells American Journal of Physiology 2005 289 4 G636 G642
11. Kunnimalaiyaan M., Chen H., The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anti-Cancer Drugs 2006 17 2 139 142
12. Nakakura E. K., Sriuranpong V. R., Kunnimalaiyaan M., Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling Journal of Clinical Endocrinology and Metabolism 2005 90 7 4350 4356
13. Jossart G. H., Grossman R. F., Clark O. H., Duh Q.-Y., McGrew L., Tumor oncogenesis Textbook of Endocrine Surgery 1997 Philadelphia, Pa, USA WB Saunders
14. Mani S., Santoro M., Fusco A., Billaud M., The RET receptor: function in development and dysfunction in congenital malformation Trends in Genetics 2001 17 10 580 589
15. Machens A., Niccoli-Sire P., Hoegel J., Early malignant progression of hereditary medullary thyroid cancer New England Journal of Medicine 2003 349 16 1517 1525
16. Santoro M., Carlomagno F., Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer Nature Clinical Practice Endocrinology and Metabolism 2006 2 1 42 52
17. Carlomagno F., Vitagliano D., Guida T., ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Research 2002 62 24 7284 7290
18. Wedge S. R., Ogilvie D. J., Dukes M., ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Research 2002 62 16 4645 4655
19. Wells S. A., Gosnell J. E., Gagel R. F., Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial Journal of Clinical Oncology 2007 25 18 supplement
20. Kim S., Yazici Y. D., Calzada G., Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Molecular Cancer Therapeutics 2007 6 6 1785 1792
21. Kim D. W., Jo Y. S., Jung H. S., An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases Journal of Clinical Endocrinology and Metabolism 2006 91 10 4070 4076
22. Hoelting T., Siperstein A. E., Clark O. H., Duh Q.-Y., Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo Journal of Clinical Endocrinology and Metabolism 1994 79 2 401 408
23. Duh Q.-Y., Gum E. T., Gerend P. L., Raper S. E., Clark O. H., Epidermal growth factor receptors in normal and neoplastic thyroid tissue Surgery 1985 98 6 1000 1007
24. Masuda H., Sugenoya A., Kobayashi S., Kasuga Y., Iida F., Epidermal growth factor receptor on human thyroid neoplasms World Journal of Surgery 1988 12 5 616 622
25. Gorla L., Mondellini P., Cuccuru G., Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements Molecular Carcinogenesis 2009 48 3 220 231
26. Folkman J., Tumor angiogenesis: therapeutic implications New England Journal of Medicine 1971 285 21 1182 1186
27. Cohen E. E. W., Rosen L. S., Vokes E. E., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study Journal of Clinical Oncology 2008 26 29 4708 4713
28. Sherman S. I., Wirth L. J., Droz J.-P., Motesanib diphosphate in progressive differentiated thyroid cancer New England Journal of Medicine 2008 359 1 31 42
29. Cohen P., Frame S., The renaissance of GSK3 Nature Reviews Molecular Cell Biology 2001 2 10 769 776
30. Kunnimalaiyaan M., Vaccaro A. M., Ndiaye M. A., Chen H., Inactivation of glycogen synthase kinase-3, a downstream target of the Raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells Molecular Cancer Therapeutics 2007 6 3 1151 1158
31. Kadesch T., Notch signaling: the demise of elegant simplicity Current Opinion in Genetics and Development 2004 14 5 506 512
32. Yoon K., Gaiano N., Notch signaling in the mammalian central nervous system: insights from mouse mutants Nature Neuroscience 2005 8 6 709 715
33. Tee Y. Y., Lowe A. J., Brand C. A., Judson R. T., Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review Annals of Surgery 2007 246 5 714 720
34. Kunnimalaiyaan M., Chen H., Tumor suppressor role of notch-1 signaling in neuroendocrine tumors Oncologist 2007 12 5 535 542
35. Kunnimalaiyaan M., Vaccaro A. M., Ndiaye M. A., Chen H., Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells Journal of Biological Chemistry 2006 281 52 39819 39830
36. Greenblatt D. Y., Cayo M. A., Adler J. T., Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells Annals of Surgery 2008 247 6 1036 1040
37. Ning L., Greenblatt D. Y., Kunnimalaiyaan M., Chen H., Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells Oncologist 2008 13 2 98 104 (Pubitemid 351342572)
38. Pinchot S. N., Pitt S. C., Sippel R. S., Kunnimalaiyaan M., Chen H., Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors Current Opinion in Investigational Drugs 2008 9 6 576 582
39. Sippel R. S., Carpenter J. E., Kunnimalaiyaan M., Chen H., The role of human achaete-scute homolog-1 in medullary thyroid cancer cells Surgery 2003 134 6 866 873
40. Vaccaro A., Chen H., Kunnimalaiyaan M., In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer Anti-Cancer Drugs 2006 17 7 849 853
41. Ravi R. K., Weber E., McMahon M., Activated Raf-1 causes growth arrest in human small cell lung cancer cells Journal of Clinical Investigation 1998 101 1 153 159
42. Ravi R. K., Thiagalingam A., Weber E., McMahon M., Nelkin B. D., Mabry M., Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells American Journal of Respiratory Cell and Molecular Biology 1999 20 4 543 549
43. Park J.-I., Strock C. J., Ball D. W., Nelkin B. D., The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway Molecular and Cellular Biology 2003 23 2 543 554
44. Ning L., Kunnimalaiyaan M., Chen H., Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway Surgery 2008 144 6 920 925
45. Hall-Jackson C. A., Eyers P. A., Cohen P., Paradoxical activation of Raf by a novel Raf inhibitor Chemistry and Biology 1999 6 8 559 568
46. Van Gompel J. J., Kunnimalaiyaan M., Holen K., Chen H., ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells Molecular Cancer Therapeutics 2005 4 6 910 917
47. Kunnimalaiyaan M., Ndiaye M., Chen H., Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways Surgery 2007 142 6 959 964
48. Malaguarnera R., Vella V., Vigneri R., Frasca F., p53 family proteins in thyroid cancer Endocrine-Related Cancer 2007 14 1 43 60
49. Saltman B., Singh B., Hedvat C. V., Wreesmann V. B., Ghossein R., Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression Surgery 2006 140 6 899 906
50. Sheikh H. A., Tometsko M., Niehouse L., Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence American Journal of Surgical Pathology 2004 28 1 101 106
51. Moretti F., Nanni S., Pontecorvi A., Molecular pathogenesis of thyroid nodules and cancer Best Practice and Research Clinical Endocrinology and Metabolism 2000 14 4 517 539
52. Wyllie F. S., Lemoine N. R., Williams E. D., Wynford-Thomas D., Structure and expression of nuclear oncogenes in multi-stage thyroid tumorigenesis British Journal of Cancer 1989 60 4 561 565
53. Terrier P., Sheng Z.-M., Schlumberger M., Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas British Journal of Cancer 1988 57 1 43 47